格卡瑞韦和哌柏西利治疗日本人类免疫缺陷病毒与丙型肝炎病毒3型合并感染患者：三例报告
Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases.
作者信息
Sho Takuya, Suda Goki, Kimura Megumi, Shimazaki Tomoe, Maehara Osamu, Shigesawa Taku, Suzuki Kazuharu, Nakamura Akihisa, Ohara Masatsugu, Umemura Machiko, Izumi Takaaki, Kawagishi Naoki, Baba Masaru, Nakai Masato, Natsuizaka Mitsuteru, Morikawa Kenichi, Ogawa Koji, Sakamoto Naoya
机构信息
Department of Gastroenterology and Hepatology, Graduate School of Medicine, Hokkaido University, Japan.
Department of Gastroenterology and Hepatology, Japan Community Health Care Organization (JCHO) Hokkaido Hospital, Japan.
出版信息
Intern Med. 2019 Mar 15;58(6):797-802. doi: 10.2169/internalmedicine.1856-18. Epub 2018 Nov 19.
The efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with human immunodeficiency virus (HIV) and/or genotype 3 hepatitis C virus (HCV) infection is yet to be clarified. This is because no or only a few patients have been included in Japanese phase 3 trials. We herein report for the first time the successful treatment of glecaprevir and pibrentasvir in three Japanese patients with HIV and genotype 3 HCV coinfection as well as hemophilia. Glecaprevir and pibrentasvir treatment is safe and effective for Japanese patients with genotype 3 HCV and HIV coinfection.
格卡瑞韦和哌仑他韦在日本人类免疫缺陷病毒（HIV）和/或3型丙型肝炎病毒（HCV）感染患者中的疗效和安全性尚未明确。这是因为日本的3期试验纳入的患者极少或没有。我们在此首次报告了3例合并HIV和3型HCV感染以及血友病的日本患者使用格卡瑞韦和哌仑他韦治疗成功的病例。格卡瑞韦和哌仑他韦治疗对于合并3型HCV和HIV感染的日本患者是安全有效的。
Zotero 插件